Loading...

ALNY ALNYLAM PHARMACEUTICALS INC Capital Structure Changes 8-K Filing

LNYL

LNY

ALNYLAM PHARMACEUTICALS INC

(ALNY)

2025 8-K

Financial Results

CEO Award Granted

Financial Results Announced

New Strategy Unveiled

Notes Repurchase

Financial Results

Credit Agreement Secured

Major Debt Offering

Convertible Notes Offering

Financial Statements

Board Retirement

Financial Results

Financial Results

Earnings Reports

Annual Meeting of Stockholders

Financial Results Announcement

Departure of Directors

Financial Results Announcement

Departure of Directors

Financial Results

Financial Results Announcement

FDA Complete Response Letter

Resignation of Director

Financial Results and Manag...

Collaboration and License A...

Annual Meeting of Stockholders

Financial Results Announcement

Board Expansion and New Dir...

Financial Results Announcement

Earnings Reports

Board Expansion and New Dir...

External Links:

On December 10, 2025, Alnylam Pharmaceuticals repurchased about $34.4 million of its convertible senior notes for approximately $51.9 million in total cost. Following this, approximately $362.8 million of the notes will remain outstanding.

AI Assistant

ALNYLAM PHARMACEUTICALS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.